Vyriad Begins First-in-Human Trial of In Vivo CAR T Therapy VV169
September 28, 2026
Phase I study will test whether a targeted lentiviral vector can generate BCMA-directed CAR T cells inside patients with multiple myeloma
3 min read
False
Advertisement
Research News
MAPK Inhibitors Restore CAR T-Cell Target in Thyroid Cancer Models
September 24, 2026
Trametinib and dabrafenib increased TSHR expression and improved the activity of CAR T cells in a patient-derived model of anaplastic thyroid cancer
2 min read
“Plug-and-Play” CAR T Platform Enables Post-Infusion Retargeting
September 23, 2026
Meditope-enabled CAR T cells can be tracked, selectively expanded, and directed toward additional tumor antigens using externally administered protein adaptors
2 min read
Long-Term Data Boost MCO-010
September 21, 2026
Four-year RESTORE results will shed new light on the durability of Nanoscope’s mutation-agnostic optogenetic therapy
2 min read
Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer
September 16, 2026
All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group
2 min read
AI-Designed Binder Improves CAR T Cell Activity in Mice
September 15, 2026
Researchers screened 1,758 de novo protein binders and identified design features that influence CAR T cell activation, specificity, and tumor control
2 min read
Biomarker Could Predict Response to Low-Dose CAR T Cell Therapy
September 14, 2026
CD27-negative, CD39-negative CAR T cells were associated with treatment response when limited cell numbers were administered
3 min read
CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis
September 8, 2026
Disease activity fell in all six participants in a phase I trial, with three achieving sustained drug-free remission during follow-up
2 min read
CAR T Before Surgery Improves Glioblastoma Control in Mice
September 7, 2026
Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival
2 min read
This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement
August 31, 2026
A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors
4 min read
